<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03427632</url>
  </required_header>
  <id_info>
    <org_study_id>PVPfortumors</org_study_id>
    <nct_id>NCT03427632</nct_id>
  </id_info>
  <brief_title>Role of Percutaneous Vertebroplasty in Treatment of Vertebral Tumors</brief_title>
  <acronym>PVP</acronym>
  <official_title>Role of Percutaneous Vertebroplasty in Treatment of Vertebral Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Percutaneous vertebroplasty is a new technique to strengthen bone and reduce pain for
      patients with vertebral tumors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Destructive vertebral lesions are a common in metastatic disease, multiple myeloma and
      lymphoma. Symptoms are caused by pathologic fracture consequences secondary to vertebral
      destruction, development of spinal instability and compression of adjacent neurological
      elements. Nonoperative treatments include radiotherapy, hormone therapy, cytotoxic drugs
      which are effective to halt the osteolytic process and reverse the neurological compromise,
      however; they cannot provide stability or relieve pain or cord compression. Surgical
      management options including vertebrectomy, reconstruction with a cage or PMMA bone cement,
      and stabilization with pedicle screws can restore spinal canal support and neurological
      functions also control pain, however; usually associated with high postoperative morbidity
      and mortality. Also not advisable for multifocal spinal disease. Percutaneous vertebroplasty
      is a new technique to strengthen bone and reduce pain. It is percutaneous, minimally
      invasive, image-guided procedure that involves injection of radio-opaque bone cement into a
      partially collapsed vertebral body, in an effort to provide stability and pain relief. The
      exact mechanism of pain relief remains unclear. Proposed theories include more favourable
      biomechanics after cement strengthening, chemical toxicity and exothermic effect of cement
      polymerization on nerve endings.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Months</target_duration>
  <primary_outcome>
    <measure>pain relief</measure>
    <time_frame>immediate</time_frame>
    <description>reduction of spine pain following the injection of bone cement in the tumor according to Numeric Rating Scale, Improvement will be considered if NRS score decrease ≧ 20% after PVP</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">11</enrollment>
  <condition>Bone Tumor</condition>
  <arm_group>
    <arm_group_label>percutaneous Vertebroplasty</arm_group_label>
    <description>patients meet the inclusion and exclusion criteria will be subjected to percutaneous vertebroplasty receiving bone cement (Polymethyl methacrylate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bone Cements</intervention_name>
    <description>patents in PVP group will get injected with bone cement inside the collapsed malignant vertebra</description>
    <arm_group_label>percutaneous Vertebroplasty</arm_group_label>
    <other_name>Polymethyl methacrylate</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Male or female patients diagnosed with vertebral body metastasis, multiple myloma, lymphoma
        meet the inclusion and exclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Spinal instability

          -  Pain with movement

          -  Multiple level involvement

          -  Expected survival 3-6 months

        Exclusion Criteria:

          -  Absolute

          -  Asymptomatic

          -  improving on medical treatment without worsening of the collapse.

          -  infection local or systemic

          -  uncorrectable coagulopathy

          -  Allergy to bone cement or contrast media

          -  Relative

          -  Radicular pain

          -  Tumor extension inside the vertebral canal or cord compression

          -  Fracture of the posterior column

          -  Sclerotic metastasis

          -  Diffuse metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Nisreen Abbas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>mustafa saed, MSc</last_name>
    <phone>01118894427</phone>
    <email>msaed9939@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assiut University hospital</name>
      <address>
        <city>Assiut</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>graduate studies, No</last_name>
      <phone>+2088 22080150</phone>
      <email>vp_grad@aun.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Alvarez L, Pérez-Higueras A, Quiñones D, Calvo E, Rossi RE. Vertebroplasty in the treatment of vertebral tumors: postprocedural outcome and quality of life. Eur Spine J. 2003 Aug;12(4):356-60. Epub 2003 Mar 22.</citation>
    <PMID>12687441</PMID>
  </reference>
  <reference>
    <citation>Melton LJ 3rd, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res. 2005 Mar;20(3):487-93. Epub 2004 Nov 29.</citation>
    <PMID>15746994</PMID>
  </reference>
  <reference>
    <citation>Wenger M, Markwalder TM. Re: Percutaneous vertebroplasty for pain relief and spinal stabilization (Spine 2000; 25: 923-8). Spine (Phila Pa 1976). 2000 Nov 15;25(22):2968-9.</citation>
    <PMID>11074686</PMID>
  </reference>
  <reference>
    <citation>Tsoumakidou G, Too CW, Koch G, Caudrelier J, Cazzato RL, Garnon J, Gangi A. CIRSE Guidelines on Percutaneous Vertebral Augmentation. Cardiovasc Intervent Radiol. 2017 Mar;40(3):331-342. doi: 10.1007/s00270-017-1574-8. Epub 2017 Jan 19.</citation>
    <PMID>28105496</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2018</study_first_submitted>
  <study_first_submitted_qc>February 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2018</study_first_posted>
  <last_update_submitted>February 3, 2018</last_update_submitted>
  <last_update_submitted_qc>February 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mustafa syd</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>PVP</keyword>
  <keyword>bone tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymethyl Methacrylate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

